A similar finding was seen when IBD LPMCs were treated with JQ1, a potent and selective pharmacological inhibitor of the BRD4 signaling pathway, thus excluding the possibility that the reduced expression of IL-34 in BRD4 AS-transfected IBD LPMCs is due to off-target effects of the AS. Here, IL34 is linked to inflammatory bowel disease.